Quarterly report · Q2
4574.TEDINET S100OZLM
Period2022-01-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.9bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥11.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥2.4bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥2.3bn | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥2.5bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥6.1bn | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥2.9bn | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥9.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥17.4bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥22.5bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥27.2bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥9.7bn | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.2bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥12.8bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥631m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥96m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥501m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.0bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-64.17 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.05 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-220.52 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.62 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.11 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 58.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | segment profit | 2022-01-01 → 2022-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥645m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥117m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.8bn |
| Otherother segments | revenue | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | revenue external | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | segment profit | 2021-01-01 → 2021-06-30 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥723m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥594m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-06-30 | −¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding write downs of inventories (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Premium allowance of retirement (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |